Globus Medical Inc

Globus Medical Inc(GMED)股票分析

$78.840

+2.617 (+3.32%)收盘时

Loading chart…
最高
79.280
开盘
77.660
成交量加权均价
78.39
成交量
1.84M
市值
9.30B
最低
77.050
成交额
143.88M
企业价值/息税折旧摊销前利润(TTM)
8.79

Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its segments include Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities. The Company also provides digital healthcare solutions.

AI 分析 of Globus Medical Inc (GMED)

持有

Currently, Globus Medical Inc is not a strong buy. The stock is priced at $74.65, which is below the average analyst price target of $85 from RBC Capital. The forward P/E ratio of 13.87 indicates it is reasonably valued, but the RSI of 47.94 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. The main risk is the insider selling, which has increased by 389.20% over the last month, signaling potential concerns about the company's future performance.

分析师评级(13)

上行空间 +28.11%
持有
5 买入
7 持有
1 卖出
当前: 78.84
最低
87.00
平均
101.00
最高
114.00

RBC Capital

2026-10-01

目标价

$85

跑赢大盘

Wells Fargo

2026-08-07

目标价

$99

增持

UBS

2026-07-28

目标价

$82

中性

Truist

2026-07-16

目标价

$100

买入

BMO Capital

2026-07-08

目标价

$94

跑赢大盘

估值指标

Globus Medical Inc(GMED)当前预期市盈率为 13.87,5 年平均预期市盈率为 23.37。

预期市盈率

低估
5 年均值 P/E
23.37
当前P/E
13.87
高估
28.91
低估
17.82

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
12.02
当前EV/EBITDA
8.79
高估
14.88
低估
9.16

预期市销率

合理
5 年均值 P/S
4.18
当前P/S
3.02
高估
5.62
低估
2.73

Alphio AI 对 GMED 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%GMED

$74.60

情景价格

基

基准

基准 · 50%GMED

$69.01

情景价格

悲

悲观

悲观 · 25%GMED

$65.33

情景价格

持有 GMED 的大户

B

Burgundy Asset Management Ltd.

+ 持有GMED

+6.98%

3个月收益率

A

American Capital Management, Inc.

+ 持有GMED

+3.92%

3个月收益率

R

Ruane, Cunniff & Goldfarb L.P.

+ 持有GMED

+2.46%

3个月收益率

C

Capital Impact Advisors, LLC

+ 持有GMED

+1.03%

3个月收益率

N

Nationwide Fund Advisors

+ 持有GMED

+0.44%

3个月收益率

A

Antipodes Partners Ltd.

+ 持有GMED

-2.49%

3个月收益率

事件时间线

2026-08-31 (ET)

08:30:00

Higgs Boson Health Acquired by Globus Medical

2026-08-26 (ET)

18:00:00

Globus Medical Acquires Higgs Boson Health

2026-05-07 (ET)

18:20:00

Company Reports Q1 Revenue of $759.85M, Beating Expectations

18:20:00

Company Reaffirms FY26 Revenue Guidance of $3.18B to $3.22B

资讯

GMED 常见问题 —— 由 Alphio AI 解答

Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its segments include Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities. The Company also provides digital healthcare solutions. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Currently, Globus Medical Inc is not a strong buy. The stock is priced at $74.65, which is below the average analyst price target of $85 from RBC Capital. The forward P/E ratio of 13.87 indicates it is reasonably valued, but the RSI of 47.94 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. The main risk is the insider selling, which has increased by 389.20% over the last month, signaling potential concerns about the company's future performance.

13 analysts cover GMED: 5 rate it Buy, 7 Hold and 1 Sell. The average price target is 101.00.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易